Alto Neuroscience (ANRO) Net Cash Flow (2023 - 2026)

Alto Neuroscience (ANRO) has 4 years of Net Cash Flow data on file, last reported at $87.3 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 1271.26% year-over-year to $87.3 million; the trailing twelve-month figure through Mar 2026 stood at $103.0 million (up 330.95% YoY), and the FY2025 full-year result was $8.3 million, down 90.39% from the prior year.
• Net Cash Flow improved to $87.3 million in Q1 2026, from $38.7 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $123.4 million in Q1 2024 to a low of -$13.5 million in Q4 2024.
• A 4-year average of $16.6 million and a median of -$7.5 million in 2025 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow sank 143.12% in 2024 and jumped 1271.26% in 2026, its largest moves.
• Tracing ANRO's Net Cash Flow over 4 years: stood at $31.3 million in 2023, then slumped by 143.12% to -$13.5 million in 2024, then jumped by 386.9% to $38.7 million in 2025, then jumped by 125.75% to $87.3 million in 2026.
• Business Quant data shows ANRO's Net Cash Flow at $87.3 million in Q1 2026, $38.7 million in Q4 2025, and -$9.8 million in Q3 2025.